Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07642050 BHV-1400 Glomerulonephritis, IGA Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07642050 clinical trial report covering BHV-1400, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07641946 Tranexamic Acid Hemoptysis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07641946 clinical trial report covering Tranexamic Acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126603 Becotatug vedotin Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126603 clinical trial report covering Becotatug vedotin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2011260018 Paclitaxel Hirschsprung Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
JPRN-jRCT2011260018 clinical trial report covering Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07644052 Gabapentin/Nabilone Marijuana Abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644052 clinical trial report covering Gabapentin/Nabilone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07645833 Eptinezumab-JJMR Pseudotumor Cerebri Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645833 clinical trial report covering Eptinezumab-JJMR, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07645924 Elismetrep Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645924 clinical trial report covering Elismetrep, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07645248 Tetrafluoroethane Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645248 clinical trial report covering Tetrafluoroethane, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071260042 HP-6050 Psychomotor Agitation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
JPRN-jRCT2071260042 clinical trial report covering HP-6050, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07644377 Riociguat Chronic thromboembolic pulmonary hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644377 clinical trial report covering Riociguat, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262251 UBT-251 Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262251 clinical trial report covering UBT-251, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262257 Viable Lactobacillus Quadruple (Sichuan Yanyang Biotechnology) Bacterial Vaginosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262257 clinical trial report covering Viable Lactobacillus Quadruple (Sichuan Yanyang Biotechnology), Phase 3, endpoints, sponsor, geography, readout